MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients

Abstract Myxovirus resistance protein A (MxA) is a molecule induced after interferon-β injection. The aim of this study was to investigate whether MxA determination one year after starting interferon-β can predict treatment response in multiple sclerosis patients. MxA mRNA expression was evaluated i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuroimmunology 2016-02, Vol.291, p.73-77
Hauptverfasser: Matas, Elisabet, Bau, Laura, Martínez-Iniesta, María, Romero-Pinel, Lucía, Mañé-Martínez, M. Alba, Cobo-Calvo, Álvaro, Martínez-Yélamos, Sergio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 77
container_issue
container_start_page 73
container_title Journal of neuroimmunology
container_volume 291
creator Matas, Elisabet
Bau, Laura
Martínez-Iniesta, María
Romero-Pinel, Lucía
Mañé-Martínez, M. Alba
Cobo-Calvo, Álvaro
Martínez-Yélamos, Sergio
description Abstract Myxovirus resistance protein A (MxA) is a molecule induced after interferon-β injection. The aim of this study was to investigate whether MxA determination one year after starting interferon-β can predict treatment response in multiple sclerosis patients. MxA mRNA expression was evaluated in blood samples obtained at baseline and at month 12. Clinical variables were prospectively recorded. A threshold of 5 was defined to establish MxA induction. On survival analysis, time to the next relapse and to EDSS progression were significantly longer in patients showing MxA induction, suggesting that MxA induction after one year may be useful to identify interferon-β responders.
doi_str_mv 10.1016/j.jneuroim.2015.12.015
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1768576457</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165572815301089</els_id><sourcerecordid>1764338991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-4313311ed8318ef1bb6c7591d04f3ba3ee342686cfd46ec88e8b2cb6c1ba05183</originalsourceid><addsrcrecordid>eNqNkstu1TAQhi0EoqcHXqHykk1ST-wkzgZxVJWLVIrUwhJZjjORnOaGJ0Ht29fRaVmwgdUs5vvn8s8wdgYiBQHFeZd2I65h8kOaCchTyNIYXrAd6DJLtMrgJdtFME_yMtMn7JSoE5GQqnrNTrJC56Wq9I79_Hp_4MPN9YHj_RyQyE8jt8Qtr_002HCHgU8t9-OCocUQkzUulkdynkbCmODD2i9-7pGT6yNBnvhsF4_jQm_Yq9b2hG-f4p79-Hj5_eJzcvXt05eLw1XiVF4siZIgJQA2WoLGFuq6cGVeQSNUK2srEaWKIxeubVSBTmvUdeYiBLUVOWi5Z--Odecw_VqRFjN4ctj3dsRpJQPltnCh8vJ_UCWlriqIaHFEXdyKArZmDj568mBAmO0KpjPPVzDbFQxkZvN4z86eeqz1gM0f2bPtEfhwBDCa8ttjMOSiYQ4bH9Atppn8v3u8_6uE6_3one3v8AGpm9YwRssNGIoCc7v9wvYKUSpA6Eo-AoffsaY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1764338991</pqid></control><display><type>article</type><title>MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Matas, Elisabet ; Bau, Laura ; Martínez-Iniesta, María ; Romero-Pinel, Lucía ; Mañé-Martínez, M. Alba ; Cobo-Calvo, Álvaro ; Martínez-Yélamos, Sergio</creator><creatorcontrib>Matas, Elisabet ; Bau, Laura ; Martínez-Iniesta, María ; Romero-Pinel, Lucía ; Mañé-Martínez, M. Alba ; Cobo-Calvo, Álvaro ; Martínez-Yélamos, Sergio</creatorcontrib><description>Abstract Myxovirus resistance protein A (MxA) is a molecule induced after interferon-β injection. The aim of this study was to investigate whether MxA determination one year after starting interferon-β can predict treatment response in multiple sclerosis patients. MxA mRNA expression was evaluated in blood samples obtained at baseline and at month 12. Clinical variables were prospectively recorded. A threshold of 5 was defined to establish MxA induction. On survival analysis, time to the next relapse and to EDSS progression were significantly longer in patients showing MxA induction, suggesting that MxA induction after one year may be useful to identify interferon-β responders.</description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/j.jneuroim.2015.12.015</identifier><identifier>PMID: 26857498</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Allergy and Immunology ; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - genetics ; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism ; Biomarker ; Biomarkers - blood ; Cohort Studies ; Disability Evaluation ; Female ; Gene Expression Regulation - drug effects ; Humans ; Immunologic Factors - therapeutic use ; Interferon-beta ; Interferon-beta - therapeutic use ; Male ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - metabolism ; Multiple Sclerosis - mortality ; MxA ; Neurology ; Prospective Studies ; RNA, Messenger - metabolism ; Statistics, Nonparametric ; Survival Analysis ; Treatment response</subject><ispartof>Journal of neuroimmunology, 2016-02, Vol.291, p.73-77</ispartof><rights>Elsevier B.V.</rights><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-4313311ed8318ef1bb6c7591d04f3ba3ee342686cfd46ec88e8b2cb6c1ba05183</citedby><cites>FETCH-LOGICAL-c456t-4313311ed8318ef1bb6c7591d04f3ba3ee342686cfd46ec88e8b2cb6c1ba05183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jneuroim.2015.12.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26857498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matas, Elisabet</creatorcontrib><creatorcontrib>Bau, Laura</creatorcontrib><creatorcontrib>Martínez-Iniesta, María</creatorcontrib><creatorcontrib>Romero-Pinel, Lucía</creatorcontrib><creatorcontrib>Mañé-Martínez, M. Alba</creatorcontrib><creatorcontrib>Cobo-Calvo, Álvaro</creatorcontrib><creatorcontrib>Martínez-Yélamos, Sergio</creatorcontrib><title>MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description>Abstract Myxovirus resistance protein A (MxA) is a molecule induced after interferon-β injection. The aim of this study was to investigate whether MxA determination one year after starting interferon-β can predict treatment response in multiple sclerosis patients. MxA mRNA expression was evaluated in blood samples obtained at baseline and at month 12. Clinical variables were prospectively recorded. A threshold of 5 was defined to establish MxA induction. On survival analysis, time to the next relapse and to EDSS progression were significantly longer in patients showing MxA induction, suggesting that MxA induction after one year may be useful to identify interferon-β responders.</description><subject>Adult</subject><subject>Allergy and Immunology</subject><subject>Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - genetics</subject><subject>Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism</subject><subject>Biomarker</subject><subject>Biomarkers - blood</subject><subject>Cohort Studies</subject><subject>Disability Evaluation</subject><subject>Female</subject><subject>Gene Expression Regulation - drug effects</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Interferon-beta</subject><subject>Interferon-beta - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - metabolism</subject><subject>Multiple Sclerosis - mortality</subject><subject>MxA</subject><subject>Neurology</subject><subject>Prospective Studies</subject><subject>RNA, Messenger - metabolism</subject><subject>Statistics, Nonparametric</subject><subject>Survival Analysis</subject><subject>Treatment response</subject><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkstu1TAQhi0EoqcHXqHykk1ST-wkzgZxVJWLVIrUwhJZjjORnOaGJ0Ht29fRaVmwgdUs5vvn8s8wdgYiBQHFeZd2I65h8kOaCchTyNIYXrAd6DJLtMrgJdtFME_yMtMn7JSoE5GQqnrNTrJC56Wq9I79_Hp_4MPN9YHj_RyQyE8jt8Qtr_002HCHgU8t9-OCocUQkzUulkdynkbCmODD2i9-7pGT6yNBnvhsF4_jQm_Yq9b2hG-f4p79-Hj5_eJzcvXt05eLw1XiVF4siZIgJQA2WoLGFuq6cGVeQSNUK2srEaWKIxeubVSBTmvUdeYiBLUVOWi5Z--Odecw_VqRFjN4ctj3dsRpJQPltnCh8vJ_UCWlriqIaHFEXdyKArZmDj568mBAmO0KpjPPVzDbFQxkZvN4z86eeqz1gM0f2bPtEfhwBDCa8ttjMOSiYQ4bH9Atppn8v3u8_6uE6_3one3v8AGpm9YwRssNGIoCc7v9wvYKUSpA6Eo-AoffsaY</recordid><startdate>20160215</startdate><enddate>20160215</enddate><creator>Matas, Elisabet</creator><creator>Bau, Laura</creator><creator>Martínez-Iniesta, María</creator><creator>Romero-Pinel, Lucía</creator><creator>Mañé-Martínez, M. Alba</creator><creator>Cobo-Calvo, Álvaro</creator><creator>Martínez-Yélamos, Sergio</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope></search><sort><creationdate>20160215</creationdate><title>MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients</title><author>Matas, Elisabet ; Bau, Laura ; Martínez-Iniesta, María ; Romero-Pinel, Lucía ; Mañé-Martínez, M. Alba ; Cobo-Calvo, Álvaro ; Martínez-Yélamos, Sergio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-4313311ed8318ef1bb6c7591d04f3ba3ee342686cfd46ec88e8b2cb6c1ba05183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Allergy and Immunology</topic><topic>Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - genetics</topic><topic>Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism</topic><topic>Biomarker</topic><topic>Biomarkers - blood</topic><topic>Cohort Studies</topic><topic>Disability Evaluation</topic><topic>Female</topic><topic>Gene Expression Regulation - drug effects</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Interferon-beta</topic><topic>Interferon-beta - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - metabolism</topic><topic>Multiple Sclerosis - mortality</topic><topic>MxA</topic><topic>Neurology</topic><topic>Prospective Studies</topic><topic>RNA, Messenger - metabolism</topic><topic>Statistics, Nonparametric</topic><topic>Survival Analysis</topic><topic>Treatment response</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matas, Elisabet</creatorcontrib><creatorcontrib>Bau, Laura</creatorcontrib><creatorcontrib>Martínez-Iniesta, María</creatorcontrib><creatorcontrib>Romero-Pinel, Lucía</creatorcontrib><creatorcontrib>Mañé-Martínez, M. Alba</creatorcontrib><creatorcontrib>Cobo-Calvo, Álvaro</creatorcontrib><creatorcontrib>Martínez-Yélamos, Sergio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matas, Elisabet</au><au>Bau, Laura</au><au>Martínez-Iniesta, María</au><au>Romero-Pinel, Lucía</au><au>Mañé-Martínez, M. Alba</au><au>Cobo-Calvo, Álvaro</au><au>Martínez-Yélamos, Sergio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>2016-02-15</date><risdate>2016</risdate><volume>291</volume><spage>73</spage><epage>77</epage><pages>73-77</pages><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract>Abstract Myxovirus resistance protein A (MxA) is a molecule induced after interferon-β injection. The aim of this study was to investigate whether MxA determination one year after starting interferon-β can predict treatment response in multiple sclerosis patients. MxA mRNA expression was evaluated in blood samples obtained at baseline and at month 12. Clinical variables were prospectively recorded. A threshold of 5 was defined to establish MxA induction. On survival analysis, time to the next relapse and to EDSS progression were significantly longer in patients showing MxA induction, suggesting that MxA induction after one year may be useful to identify interferon-β responders.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26857498</pmid><doi>10.1016/j.jneuroim.2015.12.015</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0165-5728
ispartof Journal of neuroimmunology, 2016-02, Vol.291, p.73-77
issn 0165-5728
1872-8421
language eng
recordid cdi_proquest_miscellaneous_1768576457
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Allergy and Immunology
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - genetics
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism
Biomarker
Biomarkers - blood
Cohort Studies
Disability Evaluation
Female
Gene Expression Regulation - drug effects
Humans
Immunologic Factors - therapeutic use
Interferon-beta
Interferon-beta - therapeutic use
Male
Middle Aged
Multiple sclerosis
Multiple Sclerosis - drug therapy
Multiple Sclerosis - metabolism
Multiple Sclerosis - mortality
MxA
Neurology
Prospective Studies
RNA, Messenger - metabolism
Statistics, Nonparametric
Survival Analysis
Treatment response
title MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T14%3A14%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MxA%20mRNA%20expression%20as%20a%20biomarker%20of%20interferon%20beta%20response%20in%20multiple%20sclerosis%20patients&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=Matas,%20Elisabet&rft.date=2016-02-15&rft.volume=291&rft.spage=73&rft.epage=77&rft.pages=73-77&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/j.jneuroim.2015.12.015&rft_dat=%3Cproquest_cross%3E1764338991%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1764338991&rft_id=info:pmid/26857498&rft_els_id=S0165572815301089&rfr_iscdi=true